LOCANABIO
Locanabio, Inc., is an RNA-targeting gene therapy company focused on developing therapies for patients with severe neurodegenerative, neuromuscular, and retinal diseases.
LOCANABIO
Industry:
Biotechnology Health Care Therapeutics
Founded:
2016-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.locanabio.com
Total Employee:
11+
Status:
Active
Contact:
858.285.4000
Total Funding:
155.55 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Acumen Pharmaceuticals
Acumen is developing targeted therapies for the safe and effective treatment of Alzheimer’s Disease and related neurodegenerative diseases.
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Arvinas
Arvinas advances therapies degrading disease-causing proteins for life-threatening diseases, from discovery to commercialization.
Cadent Therapeutics
Cadent Therapeutics develops novel medicines that tune and modulate brain rhythms for patients with serious neurological disease.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Jaguar Gene Therapy
Jaguar Gene Therapy is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases.
Kodiak Sciences
Kodiak is designing and developing novel therapies for the treatment of retinal disease.
Pipeline Therapeutics
Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases.
Q32 Bio
Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
UCB Ventures
UCB Ventures investment in Series B - Locanabio
ARCH Venture Partners
ARCH Venture Partners investment in Series B - Locanabio
Acuta Capital Partners
Acuta Capital Partners investment in Series B - Locanabio
GV
GV investment in Series B - Locanabio
Invus
Invus investment in Series B - Locanabio
SVB Securities
SVB Securities investment in Series B - Locanabio
Vida Ventures
Vida Ventures investment in Series B - Locanabio
RA Capital Management
RA Capital Management investment in Series B - Locanabio
Lightstone Ventures
Lightstone Ventures investment in Series B - Locanabio
Temasek Holdings
Temasek Holdings investment in Series B - Locanabio
Key Employee Changes
Official Site Inspections
http://www.locanabio.com Semrush global rank: 3.59 M Semrush visits lastest month: 4.01 K
- Host name: 230.121.231.35.bc.googleusercontent.com
- IP address: 35.231.121.230
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Locanabio"
Locanabio to Shut Down by End of Year - Global Genes
Nov 2, 2023 · Locanabio CEO Jim Burns said in a LinkedIn post that the company will shut down at the end of the year. “While we continue to believe in the potential of our RNA-targeted gene therapy platform to deliver transformative …See details»
Locanabio - Crunchbase Company Profile & Funding
Locanabio, Inc., is an RNA-targeting gene therapy company focused on developing therapies for patients with severe neurodegenerative, neuromuscular, and retinal diseases. Where is …See details»
Locanabio to close by end of 2023 - BioProcess Insider
Nov 7, 2023 · Locanabio launched in 2016 out of the University of San Diego (UC). In May 2019, the firm raised $55 million in a Series A financing round to advance and increase its pipeline of RNA-targeting gene therapy programs, …See details»
Genetic medicines biotech to ceases operations by end …
Nov 2, 2023 · Locanabio will close up shop by the end of the year as a tough market for biotechs claims another company that had been working on developing RNA medicines for rare diseases such as Duchenne...See details»
Locanabio has ceased operations
Locanabio has ceased operations. Direct all inquiries to: [email protected]See details»
Locanabio Company Profile 2024: Valuation, Funding
Developer of ribonucleic acid-targeting gene therapy platform designed for modifying disease-causing RNA for patients with rare genetic neuromuscular and neurodegenerative diseases.See details»
Locanabio Announces Equity Investment from …
SAN DIEGO, May 15, 2023 – Locanabio, Inc., a genetic medicines company developing RNA-targeted therapeutics for patients with rare genetic neuromuscular and neurodegenerative diseases, today announced that …See details»
Locanabio, Inc. | LinkedIn
At Locanabio, we are developing a new class of genetic medicines that has the potential to significantly improve the lives of patients with devastating genetic diseases by correcting the message...See details»
Gene therapy biotech Locanabio will shut down by …
Nov 1, 2023 · Gene therapy biotech Locanabio will shut down by the end of this year, the startup’s CEO posted on LinkedIn Wednesday afternoon. “While we continue to believe in the potential of our RNA-targeted gene therapy platform …See details»
Locanabio - Funding, Financials, Valuation & Investors - Crunchbase
Locana develops RNA-targeting gene therapies for patients with severe neurodegenerative, neuromuscular, and retinal diseases.See details»
Locanabio - Contacts, Employees, Board Members, Advisors
Locanabio has 9 current employee profiles, including Chairman Thomas Daniel. Locanabio has 3 board members and advisors, including Edward Conner.See details»
Locanabio Announces Equity Investment from CureDuchenne …
SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Locanabio, Inc., a genetic medicines company developing RNA-targeted therapeutics for patients with rare genetic neuromuscular …See details»
Locanabio Expands Leadership Team with Appointment of Chief …
Jul 6, 2021 · Locanabio is the global leader in developing a new class of genetic medicines. Our unique and multidimensional approach uses gene therapy to deliver RNA binding protein …See details»
Locanabio Raises $100M to Advance CRISPR-Mediated RNA …
On December 14th, Locanabio announced it had raised $100 million in a Series B financing. The funding will be used to advance the pre-clinical and clinical development of their CRISPR …See details»
Locanabio Announces Upcoming Preclinical Data Presentations at …
May 5, 2021 · Our unique and multidimensional approach uses gene therapy to deliver RNA binding protein-based systems to correct the message of disease-causing RNA and thereby …See details»
Locanabio | Biotech Careers
Locanabio is developing targeted therapies that specifically corrects dysfunctional RNA, the root cause of many devastating genetic diseases. By combining the specificity of RNA-binding …See details»
Shooting the Messenger: Locanabio Writes a New Script for RNA …
Jan 7, 2021 · Locanabio, named after the Sanskrit word for illuminating (in reference to their proof-of-concept experiments fluorescently tagging RNA), is developing therapies to treat …See details»
Locanabio to Present New Preclinical Data Demonstrating …
May 2, 2022 · Leveraging the CORRECTx platform, Locanabio is able to design multi-targeting constructs, delivered via gene therapy, that can reduce both disease-causing sense and …See details»
Locanabio Announces $100 Million Series B Financing to Advance ...
SAN DIEGO, Dec. 14, 2020 /PRNewswire/ -- Locanabio, Inc., an RNA-targeting gene therapy company focused on developing life-changing therapies for patients with severe …See details»
Locanabio Raises $100 Million to Advance RNA-Targeted Gene
Dec 14, 2020 · San Diego-based Locanabio secured $100 million in a Series B financing round that will be used to advance the company’s portfolio of novel RNA-targeted gene therapies for …See details»